Article

Family-based association study of cytotoxic T-lymphocyte antigen-4 with susceptibility to Graves' disease in Han population of Taiwan

Division of Endocrinology and Metabolism, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Genes and immunity (Impact Factor: 3.79). 04/2008; 9(2):87-92. DOI: 10.1038/sj.gene.6364445
Source: PubMed

ABSTRACT Graves' disease (GD) is a common organ-specific autoimmune disorder inherited as a complex trait. Although there has not been consensus regarding the genuine susceptibility alleles, many population-based genetic studies showed association of the cytotoxic T-lymphocyte antigen-4 (CTLA4) gene with GD. In contrast, evidence utilizing family-based studies came only from the Caucasian population. Here we performed a family-based association study in the Han population in Taiwan. We enrolled 374 affected individuals and 347 unaffected family members in 151 GD pedigrees. Four single-nucleotide polymorphisms (SNP) and a short tandem repeat polymorphism (STRP) at CTLA4 were genotyped. Association of GD with a novel risk SNP at the 5' upstream region, CTLA4_-1722_T/C (rs733618), was demonstrated (P=0.0096). We also replicated the association signal of a coding SNP, CTLA4_+49_G/A (rs231775, P=0.0219). A common haplotype composed of CTLA4_-1722_T/C and CTLA4_(AT)n (an STRP marker: UniSTS:48500) showed protective effect (P=0.0004). Our results of family-based association study, taken together with those from the Caucasian population, provide evidence that CTLA4 confers susceptibility to GD across different ethnic backgrounds.

Download full-text

Full-text

Available from: Cathy S J Fann, Mar 25, 2014
0 Followers
 · 
91 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Co-stimulatory signals are essential for the activation of naïve T cells and productive immune response. Naïve T cells receive first, antigen-specific signal through T cell receptor. Co-stimulatory receptors provide the second signal which can be either activating or inhibitory. The balance between signals determines the outcome of an immune response. CD28 is crucial for T cell activation; whereas cytotoxic T lymphocyte associated antigen 4 (CTLA4) mediates critical inhibitory signal. Inducible co-stimulator (ICOS) augments cytokine expression and plays role in immunoglobulin class switching. Programmed cell death 1 (PDCD1) acts as negative regulator of T cell proliferation and cytokine responses. The co-stimulatory receptor pathways are potentially involved in self-tolerance and thus, they provide a promising therapeutic strategy for autoimmune diseases and transplantation. The genes encoding CD28, CTLA4 and ICOS are located adjacently in the chromosome region 2q33. The PDCD1 gene maps further, to the region 2q37. CTLA4 and PDCD1 are associated with the risk of a few autoimmune diseases. There is strong linkage disequilibrium (LD) on the 2q33 region; the whole gene of CD28 exists in its own LD block but CTLA4 and the 5' part of ICOS are within a same LD block. The 3' part of ICOS and PDCD1 are in their own separate LD blocks. Extended haplotypes covering the 2q33 region can be identified. This study focuses on immune related conditions like coeliac disease (CD) which is a chronic inflammatory disease with autoimmune features. Immunoglobulin A deficiency (IgAD) belongs to the group of primary antibody deficiencies characterised by reduced levels of immunoglobulins. IgAD co-occurs often with coeliac disease. Renal transplantation is needed in the end stage kidney diseases. Transplantation causes strong immune response which is tried to suppress with drugs. All these conditions are multifactorial with complex genetic background and multiple environmental factors affecting the outcome. We have screened ICOS for polymorphisms by sequencing the exon regions. We detected 11 new variants and determined their frequencies in Finnish population. We have measured linkage disequilibrium on the 2q33 region in Finnish as well as other European populations and observed conserved haplotypes. We analysed genetic association and linkage of the co-stimulatory receptor gene region aiming to study if it is a common risk locus for immune diseases. The 2q33 region was replicated to be linked to coeliac disease in Finnish population and CTLA4-ICOS haplotypes were found to be associated with CD and IgAD being the first non-HLA risk locus common for CD and immunodeficiencies. We also showed association between ICOS and the outcome of kidney transplantation. Our results suggest new evidence for CTLA4-ICOS gene region to be involved in susceptibility of coeliac disease. The earlier published contradictory association results can be explained by involvement of both CTLA4 and ICOS in disease susceptibility. The pattern of variants acting together rather than a single polymorphism may confer the disease risk. These genes may predispose also to immunodeficiencies as well as decreased graft survival and delayed graft function. Consequently, the present study indicates that like the well established HLA locus, the co-stimulatory receptor genes predispose to variety of immune disorders. Ko-stimuloivien reseptoreiden välittämät signaalit ovat välttämättömiä naiivien T-solujen aktivoimiseksi. T-soluilla on tärkeä tehtävä immuunijärjestelmässä elimistön puolustautuessa taudinaiheuttajia vastaan. Oleellista on, että T-solut tunnistavat omat solut vieraista. Elinsiirtojen yhteydessä tarvitaankin voimakas lääkitys heikentämään immuunivastetta, joka kohdistuu elimistölle vieraita, siirrettyjä soluja vastaan. Pääsääntöisesti T-solut eivät reagoi omiin soluihin, mutta verenkiertoon pääsee joskus T-soluja, jotka hyökkäävät omaa elimistöä vastaan ja puhkeaa autoimmuunitauti kuten keliakia. Naiivit, eli antigeeniä aiemmin kohtaamattomat, T-solut tarvitsevat kaksi signaalia aktivoituakseen tehokkaiksi toimijoiksi. Ensimmäinen signaali on antigeenispesifinen ja välittyy varsinaisen T-solureseptorin kautta. Toinen, epäspesifinen signaali välittyy ko-stimuloivien reseptorien kautta. Ko-stimuloivia reseptoreita ovat mm CD28, CTLA4, ICOS ja PDCD1. Näitä reseptoreita koodittavat geenit kuuluvat samaan geeniperheeseen; ne ovat keskenään samankaltaisia ja ne sijaitsevat lähekkäin kromosomissa 2. Geeneissä on polymorfisia kohtia, joten eri yksilöillä esiintyy hieman eri muotoja samasta geenistä. Nämä periytyvät muutokset geeneissä voivat esimerkiksi altistaa yksilön keskimääräistä suuremmalle riskille sairastua autoimmuunitautiin tai siirretyn elimen hylkimiselle. Geenien eri muodot vaikuttavat siihen, miten paljon geenien koodittamia reseptoreita tuotetaan. Reseptorien muoto ja määrä puolestaan saattavat vaikuttaa siihen miten T-soluja aktivoidaan. Väitöskirjassa tutkittiin ko-stimuloivien T-solureseptoreiden geenien polymorfioita ja niiden yhteyttä keliakiaan, IgA-vasta-aineen puutokseen ja munuaissiirteen hylkimiseen. Tässä työssä etsittiin ICOS-geenistä ennen tuntemattomia polymorfisia kohtia ja määritettiin niiden yleisyys suomalaisilla. CTLA4 ja ICOS -geenien todettiin olevan hyvin läheisesti kytkeytyneet toisiinsa. Väitöskirjassa havaittiin CTLA4-ICOS-geenialueen tiettyjen polymorfoiden altistavan osaltaan keliakian puhkeamiselle. Lisäksi ICOS geenin tietyt muodot nostavat riskiä munuaissiirteen hitaalle käynnistymiselle. ICOS toimii myös immunoglobuliinien (Ig) luokanvaihdossa ja siten mahdollisesti IgA vasta-aineen puutoksen kehittymisessä. IgA-puutos ja keliakia esiintyvät usein samalla yksilöllä tai samassa perheessä. Tässä työssä havaittiin yhteinen perinnöllinen riskitekijä keliakialle ja IgA-puutokselle CTLA4-ICOS-geenialueella. Keliakian ja IgA puutoksen puhkeamiseen sekä munuaissiirteen toimivuuteen vaikuttavat useat eri geenit sekä lisäksi monet ympäristötekijät. Siten niiden ilmenemiseen vaikuttavien perinnöllisten tekijöiden tutkiminen on vaikeaa ja tulokset ovat usein tulkinnanvaraisia. CTLA4-geeniä on tutkittu paljon eri autoimmuunitauteihin liittyen. Aiemmin julkaistut ristiriitaiset tulokset voisivat selittyä sillä, että usea CTLA4-ICOS geenialueen polymorfia yhdessä (yksittäisen sijaan) lisää sairastumisriskiä.
  • [Show abstract] [Hide abstract]
    ABSTRACT: To identify and critique the most recent experimental findings regarding the pathogenesis and therapy of thyroid-associated ophthalmopathy. Much of the recent work in this field has focused on identifying genetic alterations associated with the phenotypes of Graves' disease and thyroid-associated ophthalmopathy and investigating their functional consequences. Identified candidate genes include CD40, cytotoxic T-lymphocyte antigen-4, protein tyrosine phosphatase-22, human leukocyte antigen-major histocompatibility complex and those associated with the X-chromosome. Efforts to generate a complete rodent model of Graves' disease continue with little progress. These uniformly involve the immunization of animals with the thyrotropin receptor. Studies conducted in vitro have focused on the actions of cytokines in orbital fibroblasts, the potential role of the insulin-like growth factor-1 receptor and activating antibodies directed against it as a fibroblast and T cell activation pathway. Reports continue to appear examining the potential relationship between the thyrotropin receptor and orbital adipogenesis. Regarding therapy for thyroid-associated ophthalmopathy, small molecules and antibodies disrupting cytokine pathways and lymphocyte function are currently under examination and have yielded promising albeit preliminary results. Thyroid-associated ophthalmopathy remains a vexing medical problem, the pathogenesis of which remains uncertain. A number of obstacles continue to plague major advances, not least of which is the absence of a robust animal model. A few new insights seem to represent departure from traditional thinking about this disease and may herald important innovation.
    Current opinion in endocrinology, diabetes, and obesity 11/2008; 15(5):446-52. DOI:10.1097/MED.0b013e32830eb8ab · 3.77 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: This phase II study assessed the antitumor activity of tremelimumab, a fully human, anti-CTL-associated antigen 4 monoclonal antibody, in patients with melanoma. Patients with refractory/relapsed melanoma received 15 mg/kg tremelimumab every 90 days. After 4 doses, patients with tumor response or stable disease were eligible to receive < or =4 additional doses. Primary endpoint was best overall tumor response assessed by an independent endpoint review committee, and secondary endpoints included duration of response, overall survival, progression-free survival, and safety. Of 251 patients enrolled, 246 (241 response-evaluable) received tremelimumab. Objective response rate was 6.6% (16 partial responses); duration of response was 8.9 to 29.8 months. Eight (50%) objective responses occurred in patients with stage IV M(1c) disease, and 11 (69%) were ongoing at last tumor assessment. Eight (3.3%) patients achieved responses in target lesions (Response Evaluation Criteria in Solid Tumors) despite progressive disease within the first cycle. All 8 survived for >20 months; 5 (63%) remained alive. Clinical benefit rate (overall response + stable disease) was 21% (16 partial responses and 35 stable disease), and median overall survival was 10.0 months. Progression-free survival at 6 months was 15%, and survival was 40.3% at 12 months and 22% at 24 months. Common treatment-related adverse events were generally mild to moderate, and grade 3/4 adverse events included diarrhea (n = 28, 11%), fatigue (n = 6, 2%), and colitis (n = 9, 4%). There were 2 (0.8%) treatment-related deaths. Tremelimumab showed an objective response rate of 6.6%, with all responses being durable > or =170 days since enrollment, suggesting a potential role for tremelimumab in melanoma.
    Clinical Cancer Research 02/2010; 16(3):1042-8. DOI:10.1158/1078-0432.CCR-09-2033 · 8.19 Impact Factor